Healthcare / BiotechnologyParis
$0.09
+0.00 (+1.36%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-12.9M · quality 53.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
27/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$21M
P/E
N/A
•EV/EBITDA
N/A
•ROE
48.3%
↑Gross Margin
N/A
•Debt/Equity
-0.52
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-92.7%
FCF CAGR
—
FCF margin
-917400.0%
FCF / Net income
0.76x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1000.0 · net income $-12.0M · FCF $-9.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1000.00 | $1000.00 | $1.5M | $1.3M | $2.6M |
| Net Income | $-12.0M | $-12.0M | $-14.0M | $-26.2M | $-27.6M |
| EBITDA | $-8.7M | $-8.7M | $-11.4M | $-20.9M | $-23.9M |
| EPS | -0.08 | -0.08 | -0.15 | -0.54 | -0.60 |
| Operating Margin | -1105500.0% | -1105500.0% | -1054.2% | -2343.8% | -1078.0% |
| Net Margin | -1203600.0% | -1203600.0% | -933.4% | -2069.5% | -1069.9% |
| Balance Sheet | |||||
| Debt/Equity | -0.52 | -0.52 | -0.54 | -0.60 | -0.82 |
| Current Ratio | 0.39 | 0.39 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-9.2M | $-9.2M | $-12.9M | $-24.7M | $-34.0M |
| Returns | |||||
| ROE | 48.3% | 48.3% | 52.0% | 85.4% | 179.9% |
| Growth & Yield | |||||
| Revenue Growth | -99.9% | -99.9% | 18.4% | -50.9% | — |
| EPS Growth | 46.7% | 46.7% | 72.2% | 10.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-57.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.15 → -0.08
Residual
-57.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.